Nektar Therapeutics

Company Profile

Nektar Therapeutics had its IPO on 1994-05-03 under the ticker symbol NKTR.

The company operates in the Healthcare sector and Biotechnology industry. Nektar Therapeutics has a staff strength of 216 employees.

Stock update

Shares of Nektar Therapeutics opened at $0.65 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.63 - $0.68, and closed at $0.66.

This is a +1.34% increase from the previous day's closing price.

A total volume of 2,260,542 shares were traded at the close of the day’s session.

In the last one week, shares of Nektar Therapeutics have increased by +9.78%.

Nektar Therapeutics's Key Ratios

Nektar Therapeutics has a market cap of $123.58 million, indicating a price to book ratio of 1.2767 and a price to sales ratio of 5.3395.

In the last 12-months Nektar Therapeutics’s revenue was $87.74 million with a gross profit of $70.42 million and an EBITDA of $-139094000. The EBITDA ratio measures Nektar Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nektar Therapeutics’s operating margin was -170.3% while its return on assets stood at -13.77% with a return of equity of -93.6%.

In Q2, Nektar Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5%.

Nektar Therapeutics’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

3.22

Its diluted EPS in the last 12-months stands at $-1.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 3.22. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nektar Therapeutics’s profitability.

Nektar Therapeutics stock is trading at a EV to sales ratio of 1.2051 and a EV to EBITDA ratio of -0.2787. Its price to sales ratio in the trailing 12-months stood at 5.3395.

Nektar Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$494.28 million

Total Liabilities

$50.69 million

Operating Cash Flow

$25.17 million

Capital Expenditure

$162000

Dividend Payout Ratio

0%

Nektar Therapeutics ended 2024 with $494.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $494.28 million while shareholder equity stood at $196.96 million.

Nektar Therapeutics ended 2024 with $0 in deferred long-term liabilities, $50.69 million in other current liabilities, 19000.00 in common stock, $-3389333000.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $50.73 million and cash and short-term investments were $409.43 million. The company’s total short-term debt was $18,933,000 while long-term debt stood at $0.

Nektar Therapeutics’s total current assets stands at $441.06 million while long-term investments were $0 and short-term investments were $358.70 million. Its net receivables were $1.34 million compared to accounts payable of $2.62 million and inventory worth $20.69 million.

In 2024, Nektar Therapeutics's operating cash flow was $25.17 million while its capital expenditure stood at $162000.

Comparatively, Nektar Therapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.66

52-Week High

$4.37

52-Week Low

$0.51

Analyst Target Price

$2.38

Nektar Therapeutics stock is currently trading at $0.66 per share. It touched a 52-week high of $4.37 and a 52-week low of $4.37. Analysts tracking the stock have a 12-month average target price of $2.38.

Its 50-day moving average was $0.64 and 200-day moving average was $1.35 The short ratio stood at 0.53 indicating a short percent outstanding of 0%.

Around 106.7% of the company’s stock are held by insiders while 9738.3% are held by institutions.